High Content Solid Dispersions for Dose Window Extension: A Basis for Design Flexibility in Fused Deposition Modelling by Govender, Rydvikha et al.
High Content Solid Dispersions for Dose Window Extension: A Basis
for Design Flexibility in Fused Deposition Modelling
Downloaded from: https://research.chalmers.se, 2021-08-31 12:59 UTC
Citation for the original published paper (version of record):
Govender, R., Abrahmsén-Alami, S., Folestad, S. et al (2020)




N.B. When citing this work, cite the original published paper.
research.chalmers.se offers the possibility of retrieving research publications produced at Chalmers University of Technology.
It covers all kind of research output: articles, dissertations, conference papers, reports etc. since 2004.
research.chalmers.se is administrated and maintained by Chalmers Library
(article starts on next page)
RESEARCH PAPER
High Content Solid Dispersions for DoseWindow Extension: A
Basis for Design Flexibility in Fused Deposition Modelling
Rydvikha Govender1,2 & Susanna Abrahmsén-Alami1 & Staffan Folestad1 & Anette Larsson2
# The Author(s) 2019
ABSTRACT
Purpose This study uses high drug content solid dispersions for dose window extension beyond current demonstrations using
fused deposition modelling (FDM) to; i) accommodate pharmaceutically relevant doses of drugs of varying potencies at accept-
able dosage form sizes and ii) enable enhanced dose flexibility via modular dosage form design concepts.
Methods FDM was used to generate ~0.5 mm thick discs of varying diameter (2–10 mm) from melt-extruded feedstocks based
on 10% to 50% w/w felodipine in ethyl cellulose. Drug content was determined by UV spectroscopy and dispensing precision
from printed disc mass.
Results Mean felodipine content was within ±5% of target values for all print volumes and compositions including contents as
high as ~50% w/w. However, poor dispensing precision was evident at all print volumes.
Conclusions In pursuit of dose flexibility, this successful demonstration of dose window extension using high content solid
dispersions preserves FDM design flexibility by maintaining applicability to drugs of varying potencies. The achieved uniformity
of content supports the application of varying content solid dispersions to modular dosage form concepts to enhance dose
flexibility. However, poor dispensing precision impedes its utilisation until appropriate compatibility between FDM hardware
and materials at varying drug contents can be attained.
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ABBREVIATIONS
AM Additive manufacturing
API Active pharmaceutical ingredient
DSC Differential scanning calorimetry
EC Ethyl cellulose
FDM Fused deposition modelling
FEL Felodipine
HME Hot melt extrusion
TGA Thermogravimetric analysis
INTRODUCTION
Fused deposition modelling (FDM) is an additive manufactur-
ing (AM) technology based onmaterial extrusion. Specifically,
FDM involves feeding of a thermoplastic polymeric filament
through a heated nozzle where it melts or softens for subse-
quent layer-by-layer deposition on a platform (1). Like AM
technologies in general, the versatility, freedom of design and
formation of complex, customizable parts makes FDM attrac-
tive for pharmaceutical applications (2), particularly for the
generation of individualized products (3–6). FDM is preceded
by hot melt extrusion (HME) to develop a filament feedstock
for the FDM process. HME, involving the mixing of materials
by rotating screws under elevated temperature and shear, is
widely used for the formation of solid dispersions of drugs in
polymeric carriers (7,8). It is claimed to enable homogeneous
drug distribution particularly when solid solutions (molecular
dispersions) of a drug in the polymeric carrier are formed
(6,8–10). This provides a distinct benefit for flexible dosing.
Patients’ needs for flexible dosing are ascertained from multi-
ple characteristics (e.g. genetics, age, body weight, disease
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severity, comorbidities, adherence, food-drug and drug-drug
interactions), which vary between individuals and within the
same individual over time (11–16). Tailoring the dose to these
characteristics to promote safety and effectiveness necessitates
the provision of an increased number of dose strengths in the
product offering (17).
Dose flexibility has been demonstrated previously using the
current state of the art in FDM. One approach used to pro-
vide flexibility is alteration of dosage form size to accommo-
date varying dose strengths (18–20). Drug loading has, until
now, been based on a filament of low drug content, for exam-
ple 2%w/w (21) and as low as 0.29%w/w (1) for drug loading
methods based on passive diffusion of drug from solution into
commercially available pre-extruded filaments of high diam-
eter tolerances. Consequently, dose ranges that have been
demonstrated so far, for conventional FDM, are often insuffi-
cient to incorporate pharmaceutically relevant doses of inter-
mediate to low potency drugs without resulting in unaccept-
ably large dosage forms. Although lab-scale compounding of
filaments by HME from physical mixtures of drug and carrier
broadens the scope of materials that can be used and enables
improved drug loading, co-processing the drug and polymer
may introduce variations in rheological properties and fila-
ment diameter (18,22). This not only has implications for
FDM printability and repeatability downstream but has lim-
ited the study of high drug content compositions in current
literature. Few studies have attempted to vary the dose inde-
pendent of dosage form size e.g. by altering the infill percent-
age of printed units (1), however, these are still based on low
payload filaments.
To the best of our knowledge, size-independent dose flex-
ibility at pharmaceutically relevant doses has not yet been
demonstrated with conventional FDM and has instead re-
quired modification of printer hardware e.g. co-ordinated 3D
printing and liquid dispensing (23). In addition to a limited
dose range achievable with the dose-dependent dosage form
size approach, the extent of flexibility, i.e. the number of dose
increments within the dose range, is directly dependent on the
number of discrete filament compositions that can be
produced.
In response to the aforementioned drawbacks in current
attempts at dose flexibility using FDM, we suggest the use of
high drug content solid dispersions to extend the dose window
to accommodate pharmaceutically relevant doses of drugs of
varying potencies at acceptable dosage form sizes (Fig. 1).
Our suggested approach is derived from the following hy-
pothesis: Uniformity of drug content in printed units, a pre-
requisite for dose flexibility, can be concurrently achieved at
high feedstock drug contents and small print volumes, provid-
ed that homogeneity is maintained at an equivalent or smaller
length scale in the feedstock than the size of a printed unit.
In most cases, drug-containing FDM-printed units encoun-
tered in the current literature have dimensions in the same
order of magnitude as conventional tablets (1,19,20,24,25).
For a standard size dosage form, a greater degree of dose
flexibility can be achieved if the dosage form is comprised of
smaller modules, e.g. pellets (26). This will entail printing of
smaller volumes of each module than the size of a final dosage
form. Our study therefore aims to investigate uniformity of
drug content at 10, 30 and 50% w/w API and at small print
volumes ranging from ~2 to ~40 mm3.
A model system comprising felodipine (FEL) as the model
drug and ethyl cellulose (EC) as the polymeric carrier was
selected based on an inherently low tendency of FEL to re-
crystallize from the amorphous form (27), which is further
promoted by the ability of EC to stabilize FEL in amorphous
form (28,29). This system was postulated to form sufficiently
stable amorphous solid dispersions at high drug contents with-
out a tendency to introduce large domain inhomogeneity via
recrystallization or amorphous phase separation prior to
FDM, allowing investigation of the study aims.
MATERIALS AND METHODS
Materials
FEL (MW 384.26 g/mol) was obtained from AstraZeneca,
Sweden. EC (Ethocel™ Standard 20 Premium) was supplied




The onset of thermal degradation (Tdeg) was determined by
thermogravimetric analysis (TGA) using a TGA/DSC 3+
STARe system instrument (Mettler Toledo, Switzerland).
Tdeg was calculated as the extrapolated onset temperature in
the weight vs. temperature curve. FEL and EC powders were
weighed in open 70 μl alumina crucibles and heated from
25°C to 350°C at 10 K/min under a nitrogen atmosphere
set at a flow rate of 50 ml/min.
Differential scanning calorimetry (DSC) in a DSC 2
STARe system instrument (Mettler Toledo, Switzerland) was
used to measure both the glass transition temperatures (Tg)
and melting points (Tm) of FEL and EC powders as well as
HME filaments after 24 h storage in sealed plastic bags at
ambient conditions. Tg values were determined at the mid-
point of the Tg range and Tm at the peak of the melting
endotherm. Each sample was weighed in a 40 μl aluminium
crucible, which was sealed by a lid with pinhole for subsequent
analysis. The instrument was run in a heat-cool-heat cycle at
10 K/min from 25°C to 210°C under a nitrogen atmosphere
with a flow rate of 50 ml/min. STARe software (version
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16.00b, Mettler Toledo, Switzerland) was used for instrument
control and subsequent analysis of thermograms.
HME
Three compositions were prepared corresponding to 10%
w/w, 30% w/w, and 50% w/w FEL in EC, which are desig-
nated FEL10, FEL30, and FEL50, respectively. FEL10HME,
FEL30HME, and FEL50HME represent hot melt extruded
filaments at each FEL concentration. EC powder and FEL
powder were weighed in glass vials in approximately 2.5 g
batches and mixed until homogeneous upon visual inspection.
HME was performed using a 5 ml capacity Xplore micro
compounder (Xplore, The Netherlands), affixed with conical
mixing screws and a circular die 1.5 mm in diameter. The
physical mixtures were fed via a hopper into the barrel main-
tained at a constant temperature profile of 150°C and a screw
speed of 50 rpm during feeding, recirculation and ejection, for
all compositions. After complete feeding (˂ 1 min), melted
mixtures were recirculated for 10 min to aid homogenization
prior to manual extrusion through the die to obtain a cylin-
drical filament, which was allowed to cool at ambient temper-
ature. After extrusion, the length of each filament was mea-
sured and the diameter was verified every 5 cm using digital
calipers. Filaments were stored in sealed plastic bags at ambi-
ent temperature prior to characterisation or processing by
FDM.
FDM
AZMorphVXmultitool 3D printer (ZMorph S.A.,Wroclaw,
Poland), equipped with a single 0.3 mm diameter extrusion
nozzle, was used to print disc-shaped units according to a
digital model created using Autodesk® TinkerCAD™
(Autodesk, Inc., San Rafael, CA, USA). Discs were designed
in 5 diameter variants including 2, 4, 6, 8, and 10 mm, all
0.5 mm thick. Calculated target volume for each variant was
1.6, 6.3, 14.1, 25.1, and 39.3 mm3, respectively. The gener-
ated ‘.stl’ file was subsequently imported into Simplify3D®
(version 4.1.1., Simplify3D LLC) for control of printing pa-
rameters and subsequent printing. The build platform was
levelled and heated to 80°C prior to printing of discs. After
24 h of storage at ambient temperature, prepared filaments
were manually fed into a 0.3 mm nozzle onto the heated glass
build platform overlaid with a polyethylene terephthalate
(PET) film to facilitate adhesion and aid detachment of thin
discs upon cooling. Due to filament breakage when inserted
into a filament feeding mechanism based on rotating gears,
automated feeding was not achievable. Nozzle temperature
was adjusted to 195°C, 170°C, and 155°C for FEL10,
FEL30, and FEL50, respectively, ensuring suitable melt flow
for printability. FEL10FDM, FEL30FDM, and FEL50FDM
represent FDM-printed discs at each FEL content.
FEL Assay in HME Filaments and FDM Discs
Ten 0.5 cm samples were obtained from each filament at a
minimum of 5 cm intervals to allow sample collection over the
length of the entire extruded filament, with longer intervals for
longer filaments. The first 2.5 cm, corresponding to the ex-
truder die length, was excluded. A total of 60 samples were
obtained from 2 filaments per composition. Each 0.5 cm fila-
ment section was weighed with a Mettler MT5 analytical bal-
ance (Mettler Toledo, Switzerland) and dissolved, whilst stir-
ring, in 10 ml 95% ethanol at ambient temperature for 24 h.
Discs generated by FDMwere weighed and dissolved as for
HME filaments but solvent volumes for dissolution of discs
were adapted to disc size (5 ml for 2 mm discs, 10 ml for 4–
8 mm discs and 20 ml for 10 mm discs) to allow solvent vol-
umes sufficiently above the solubility limit of FEL and EC in
ethanol. Disc duplicates (2 mm to 10 mm) were printed from
each of two filaments per composition resulting in a total of 30
discs for FEL assay.
Fig. 1 Enabling dose flexibility for individualization by use of high drug content solid dispersions in FDM for dose window extension relative to current
demonstrations.
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Amber glassware was used for all analyses. FEL content
was determined by analysing sample solutions with a Cary60
UV-Vis spectrophotometer (Agilent Technologies, Inc., CA,
USA). Cary WinUV scan application software (version
5.0.0.999, Agilent Technologies, Inc., CA, USA) was used
for instrument operation and spectral acquisition. Sample so-
lutions were analysed at a scan rate of 4800 nm/min from 800
to 290 nm, excluding lower wavelengths due to degradation of
FEL at these wavelengths. Absorbance readings at a lambda
max of 362 nm were used to calculate FEL content. Linearity
was confirmed by a calibration curve of FEL in 95% ethanol
over the range 5 to 45 μg/ml. Absence of interaction between
FEL and EC in solution was confirmed by UV absorbance
measurements of a 1:1 mixture of FEL and EC solutions at
20 μg/ml. Prior to analysis, sample solutions were diluted, as
required, in 95% ethanol to fall within this range. UV absor-
bance measurements were performed in triplicate for each
sample solution.
Fourier Transform Raman Spectroscopy
Fourier transform Raman spectroscopy (FT-Raman
spectroscopy) was performed on raw materials and extruded
filaments (FEL10HME, FEL30HME, and FEL50HME). A
MultiRAM FT-Raman spectrometer (Bruker OPTIK
GmbH, Ettlingen, Germany) was used, equipped with an
Nd:YAG laser excitation source operating at 1064 nm.
OPUS Version 7.5 (Bruker OPTIK GmbH, Ettlingen,
Germany) was used for instrument operation and data acqui-
sition. Spectra were recorded as an average of 256 scans for
each sample at a laser power of 500 mW to obtain a good
signal-to-noise ratio at a resolution of 2 cm−1. FEL and EC
powders were placed in nuclear magnetic resonance (NMR)
tubes and filament sections obtained mid-length from the total
extruded length were mounted directly on a sample holder
before placing in the optical path of the spectrometer. For
the amorphous FEL reference, FEL powder was placed in
an NMR tube and heated in a vacuum oven at 150°C until
FEL powder was melted.
RESULTS
Uniformity of Drug Content
Figure 2 shows FEL content as a% of target content in printed
discs after normalizing to mass, where target content was de-
fined as 8.8% w/w, 25.9% w/w, and 42.8% w/w FEL for
FEL10, FEL30, and FEL50, respectively, denoting filament
FEL content after the corresponding extrusion step. Mean
FEL content, to the nearest whole number, was within 5%
of target values and individual FEL contents were within 10%
of target values at all drug contents and all print volumes, even
for the high FEL content composition (FEL50FDM).
The tendency of drugs to aggregate typically increases with
concentration, potentially impacting both stability against re-
crystallization and homogeneity. Regarding homogeneity, this
is therefore a critical finding since the use of high content solid
dispersions is a prerequisite for achieving dose flexibility at
pharmaceutically relevant doses. To this end, achieving an
accurate and precise target dose in printed discs at predicted
print volumes ranging from 1.5 to 39 mm3 was hypothesized
to be dependent on homogeneity in the filament extrudate on
an equivalent or smaller scale than the desired print volume.
Indeed, the FEL content in sections of extruded filaments
spanning the full length of each filament at sample volumes
~ 0.9 mm3 revealed low standard deviations in FEL content at
all compositions (Fig. 3), indicating HME filament homoge-
neity suitable for subsequent FDM printing.
Target FEL content was 10% w/w, 30% w/w, and 50%
w/w FEL for FEL10, FEL30, and FEL50, respectively, from
physical mixtures before HME. Although the measured FEL
content in HME filaments was lower than the target FEL
content for all compositions (Fig. 3), it is evident that the fila-
ments from the second extrusion have a higher FEL content
(86–88% of target content) than the filaments from the first
extrusion (74–78% of target content) at all compositions. Due
to incomplete emptying of the barrel between compositions
despite mechanical cleaning, this was largely attributed to
carry-over of residue containing both drug and polymer from
the preceding extruded composition of lower FEL content.
The below-target FEL contents were a consequence of both
incomplete emptying of the barrel between compositions and
the order in which the compositions were extruded (from low-
est to highest FEL content) following an initial priming of the
extruder with pure EC, resulting in dilution of each subse-
quent extruded composition as residual material was
replenished with incoming material. Residual material in the
extruder barrel and on the screws would be a much less pro-
nounced issue in a scaled-up process when equipment with a
smaller effective surface area per unit volume, screw designs
Fig. 2 Mean FEL content as a % of target FEL content in FDM discs at each
composition and disc size; each bar=mean± SD of n =4 discs.
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suited to optimal conveying, and continuous feeding of pow-
der feedstocks to maintain a constant barrel pressure, are
implemented.
Since the HME and FDM processes are run in batch mode
via two distinct unit processes, acquired homogeneity after
HME must be maintained in the storage period prior to
FDM printing, which was investigated and confirmed using
FT Raman spectroscopy and DSC. Figure 4 shows Raman
spectra of raw materials and HME filaments in the lattice
mode region (Fig. 4a) and the fingerprint region (Fig. 4b)
measured 2 weeks after HME. The lattice mode region of
the Raman spectrum allows rapid discrimination between
solid-state forms and could therefore be used to denote
process-induced changes in the solid-state form of FEL there-
by confirming an absence of recrystallization after storage at
ambient conditions prior to FDM.
Crystalline FEL displays a characteristic sharp band at
96 cm−1 in accordance with the literature (30), which is not
present in the amorphous FEL or in the extruded filaments
(Fig. 4a). The fingerprint region of crystalline FEL powder
also reveals a crystalline FEL band at 1701 cm−1
corresponding to the methyl ester carbonyl of FEL (31) (Fig.
4b). Whilst this peak is present in amorphous FEL and in
HME filaments, it is broader and poorly resolved from the
adjacent peak (30). This indicates an absence of FEL recrys-
tallization in extruded filaments prior to FDM. Furthermore,
the relative intensity of the amorphous FEL peak at
1494 cm−1 to the EC peak at 1459 cm−1 increases as FEL
content in the filament increases, indicating that the acquired
spectra are representative of expected FEL contents in the
bulk filament. Taken together, the fingerprint region confirms
the presence of FEL in expected proportions to the carrier in
all extruded filaments and the lattice mode region confirms
process-induced changes in FEL from crystalline to amor-
phous. This result is in agreement with the absence of FEL
melting endotherms in the first heat cycle of DSC of extruded
filaments (Fig. 5).
The peaks at 60°C and 54°C for FEL30HME and
FEL50HME, respectively, overlay the Tg and correspond to
molecular relaxation upon heating above Tg as a consequence
of relieving extrusion-induced stresses present in these fila-
ments (Fig. 5) (32).
If FEL aggregates were present in our system at high FEL
contents, they were amorphous and not detectable as a second
Tg during DSC, but more significantly, they did not hinder
obtaining mean FEL content within 5% of target values. The
formation of solid solutions is not a strict requirement for
accurate and precise flexible dosing but, in accordance with
our hypothesis, the extent of homogeneity, given by the size
and distribution of aggregates, must be appropriate for the
desired print volume.
Dispensing Precision
The initial processing window was determined from the ther-
mal properties of the raw materials as measured by TGA and
DSC on raw materials. The upper limit for processing tem-
peratures during HME was defined by the Tdeg whereas the
lower limit was defined by the Tg and Tm, as reported in
Table I. It is recommended that HME be performed 20–
Fig. 4 Raman spectra of raw
materials and HME filaments in (a)
the lattice mode region and (b) the
fingerprint region.
Fig. 3 Mean FEL content as a % of target FEL content in HME filaments at
each composition; 1 and 2 denote sequential extrusion steps; each bar =
mean± SD of n =10 sections from the same filament.
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40°C above Tg to maintain the polymer in a rubbery state at a
suitable melt viscosity for extrusion. Based on the results in
Table I, an extrusion temperature of 150°C was found to be
suitable, which would also allow melting of crystalline FEL
(33).
Precise dispensing requires consistent melt flow from the
FDM nozzle. To achieve this, FDM is generally performed at
temperatures higher than HME to compensate for the rela-
tively short residence time of the filament in the FDM lique-
fier, however, processing temperatures must also account for
the potential influence of the drug on melt flow at different
compositions. To determine the required adjustment of pro-
cessing temperature for FDM, Tg of extruded filaments of
varying compositions was determined to investigate the influ-
ence of FEL on the Tg of the binary mixture of FEL and EC
during processing. The Gordon-Taylor Eq. (1) is a model
widely used to explain the composition dependence of the
Tg in amorphous binary mixtures, e.g. plasticization and
anti-plasticization (34). The Tg mix of the mixture is derived
from contributions of the pure components (Tgi) and is defined
as
T g mix≈ ω1:T g1 þ K :ω2:T g2
 
= ω1 þ K :ω2½  ð1Þ
where ω1 and ω2 are the mass fractions of each component,
Tg1 and Tg2 are their respective glass transition temperatures,
and the constant K is an adjustable fitting parameter.
Notably, the Gordon-Taylor equation is based on volume
additivity and assumes ideal volume mixing of both
components in the absence of specific interactions, resulting
in linearity of the dashed line in Fig. 6.
Experimentally obtained Tg values display a convex down-
ward deviation from the linear Gordon-Taylor model (Fig. 6).
This nonlinear decrease in Tg as a function of filament com-
position indicates that the Tg of FEL predominates in intensity
in the binary mixture and confirms plasticization of EC by
FEL. It may be attributable to intermolecular forces between
FEL and EC, which manifest as specific interactions between
functional groups of FEL and EC, however, this cannot be
inferred from deviations from Gordon-Taylor alone
(27,28,34,35). Nevertheless, such deviations have been dem-
onstrated previously for FEL in cellulosic carriers (36).
Interestingly, at low FEL contents, Tg of themixture decreases
approximately in proportion to the weight fraction of the low-
er Tg component, FEL, which may indicate a well-mixed
system until the levelling out of Tg beyond 50% w/w FEL,
which may suggest phase separation into a second FEL-rich
Table I Onset of Thermal Degradation Tdeg (°C), Glass Transition
Temperature Tg (°C) and Melting Point Tm (°C) of Raw Materials
舃Material 舃Tdeg (°C) 舃Tg (°C) 舃Tm (°C)
舃FEL powder 舃287 舃~45 舃148
舃EC powder 舃300 舃~128 舃185
Fig. 5 DSC traces of extruded
filaments (black lines) relative to raw
materials (red lines) for heat cycle 1.
Fig. 6 Tg vs. nominal FEL content (% w/w) in HME filaments. Dashed red
line denotes linear Gordon-Taylor model. Pure FEL Tg determination was
performed on powder due to an inability to extrude pure drug.
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phase as one or more FEL aggregates. Whilst this is in agree-
ment with previous observations for mixtures of FEL and
HPMC or HPMCAS (36,37), as indicated in section 3.1, it
did not impact attaining target FEL contents.
Despite modification of FDM printing temperatures to ac-
count for plasticization of EC by FEL, large relative standard
deviations in mean mass reveal poor dispensing precision
(Fig. 7).
This reflects variations in disc thickness at the level of a
single disc for all print volumes in this study. Since filament
brittleness prevented automated feeding, this dispensing im-
precision likely signals a sensitivity to manual feeding rates
(38,39). However, mass deviations revealing over-extrusion
and under-extrusion from the FDM nozzle were encountered
previously, despite automated feeding, at both larger print
volumes (74 to 468 mm3) (21) and smaller print volumes
(20). This could, in part, be due to filament diameter varia-
tions. Mean filament diameters were 1.54 ± 0.09, 1.49 ± 0.14
and 1.34 ± 0.08 for FEL10HME, FEL30HME and
FEL50HME, respectively (n ≥ 28 filament sections measured)
in our study. Furthermore, the greater imprecision observed
at smaller dispensing volumes implies that inconsistent depo-
sition rates of the melt from the FDM nozzle is an additional
contributor to dispensing imprecision.
DISCUSSION
General Applicability of the High Drug Content
Approach in Promoting Flexibility of the FDM
Platform
Figure 8 depicts the extension of the dose window, relative to
that demonstrated by current studies, exemplified for a
standard-sized 200 mg dosage form comprising multiple small
volume printed units manufactured using the high drug con-
tent approach in this study.
Dose flexibility currently demonstrated by FDM, involving
the use of comparatively lower drug content feedstocks, are
depicted for comparison (19–21). A greater than eight-fold
extension of the upper limit of the dose window, relative to
the maximum dose demonstrated in current literature, has
been achieved in this study. The dose range for a 200 mg
dosage form was calculated based on mean measured drug
content in the printed discs of 8.6, 25, and 41.8% w/w FEL
for FEL10FDM, FEL30FDM, and FEL50FDM, respectively.
The dotted arrow signifies that a lower dose range is accessible
via the use of lower feedstock drug contents or incorporation
of placebo modules for modular product design concepts.
To enhance dose flexibility within the extended dose range
enabled by the use of high drug content feedstocks, we suggest
that combining a limited number of discrete feedstock com-
positions, spanning a wide range of drug contents, could pro-
vide a several-fold increase in the number of dose levels for a
dosage form. This transition from a monolithic to modular
dosage form design concept is workable via the use of multiple
nozzles during FDM whilst allowing an increased number of
dose levels to be generated from relatively fewer starting fila-
ment compositions (Fig. 9), thereby enhancing dose flexibility
without a need to generate a designated filament for each
desired dose strength.
As depicted in Fig. 9, maintaining acceptable dosage form
sizes independent of the dose strength requires printed mod-
ules which are a fraction of the size of a conventional dosage
form. Since the success of this approach relies on maintaining
homogeneity in the feedstock at an equivalent or smaller
length scale than the size of a printed module rather than
the size of a final dosage form, a modular approach imposes
stricter requirements on feedstock homogeneity than the
Fig. 8 Extension of FDM dose window with the high drug content approach
relative to the low drug content approaches based on 0.063% (20), 0.236%
(20), 1% (19) and 1.9% (21) w/w API in feedstocks demonstrated in current
literature.
Fig. 7 % Relative standard deviation (RSD) in mean mass vs. print volume
(mm3), n ≥ 27.
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generation of conventional dosage form monoliths. By dem-
onstrating individual drug contents within 10% of the target
and mean drug contents within 5% of the target for drug
contents up to 42.8% w/w FEL at print volumes relatively
smaller than a conventional dosage form, this study has not
only confirmed the feasibility of the high drug content ap-
proach but notably, can preserve FDM design flexibility by
maintaining applicability to a broad range of APIs of varying
potencies at conventional dosage form sizes. By extension, for
accurate, tailored dosing, the higher the content and smaller
the volume that maintains both uniformity of drug content
and mass, the greater the potential dose flexibility which
may be realised with FDM. Modular product concepts can
then be realised in one of two ways, namely, by physical as-
sembly of pre-manufactured subunits or by virtual assembly of
various feedstocks or designs via FDM’s .gcode print instruc-
tion. The former approach would rely on stability against
drug recrystallization for the pre-manufactured subunits at
their small size when incorporating drugs with poor aqueous
solubility.
The Relevance of Amorphous Systems
The maximum drug content to form an amorphous solid dis-
persion with the desired degree of homogeneity will vary for
different APIs and different carriers depending on factors such
as drug-polymer solubility, stability against recrystallization,
storage conditions, and so forth. In this study, the mainte-
nance of FEL in amorphous form after production as solid
dispersions has been confirmed with FT-Raman spectroscopy
and DSC. However, although we have considered recrystalli-
zation a qualitative indicator of large domain inhomogeneity,
neither the formation of solid solutions nor maintenance of the
drug in amorphous form are strict prerequisites for dose flex-
ibility. In non-molecularly dispersed systems, the smallest
printable module and thus the number of dose increments
and degree of dose flexibility will depend upon the size and
distribution of aggregates in the system. For the sole purpose
of dose flexibility, stable crystalline systems or aggregated
amorphous systems are also acceptable, however, clinical rel-
evance for poorly soluble APIs in the case of the former, es-
pecially at low potencies, may not be optimal. Crystalline dis-
persions of poorly aqueous soluble drugs will require higher
doses to obtain an equivalent therapeutic effect relative to
amorphous formulations of the same drug. The relatively
higher feedstock payload that would be needed to deliver a
high dose of a crystalline, poorly aqueous soluble drug may
compromise homogeneity, depending on the size and distri-
bution of the crystallites. Consequently, our confirmation of
FEL in amorphous form at all drug contents in this study also
preserves ideal FDM applicability to APIs with poor aqueous
solubility.
The Role of Dispensing Precision in Enhancing
Dose Flexibility
Poor dispensing precision at all print volumes and all drug
contents in this study was largely attributed tomanual feeding.
Consistent, automated feeding is a key requirement for preci-
sion dispensing during FDM as well as for future scale-up of
Fig. 9 Modular dosage form
design concept to enhance dose
flexibility.
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the FDM platform. This, in turn, relies upon a filament feed-
stock with high diameter tolerances and either filament feed-
ing mechanisms adaptable to a wide range of filament prop-
erties or restriction to use of suitable materials or optimisation
of formulations for the types of feeding mechanisms available.
Beyond compatibility with current FDM feeding mechanisms,
filaments for FDM are required to simultaneously fulfil a host
of thermal, mechanical and rheological properties whilst pro-
viding the relevant pharmaceutical function (38).
In addition to feeding into the nozzle without filament
breakage or deformation, in the absence of wide temperature
processing windows, materials of variable rheological proper-
ties need to be accurately and consistently dispensed from the
nozzle, which necessitates novel engineering solutions for both
nozzle and feeding mechanism design.
A key advantage of modularized dosage form designs for
scalable dosing is that a designated filament need not be pro-
duced for each delivered dose, which is potentially beneficial
regarding HME-FDM production process efficiency and
costs. The uniformity of drug contents demonstrated in this
study fully support this approach, however, until a superior
level of dispensing precision can be established on a single
module level (at sub-dosage form sizes), achieving scalable
dosing via modularized designs cannot be realised yet.
CONCLUSIONS
Extension of the upper limit of the dose window by more than
eight times the maximum dose encountered in existing litera-
ture has been demonstrated in this study via the use of high
drug content solid dispersions, which is a prerequisite for
pharmaceutically relevant dose flexibility. The versatility and
design flexibility of FDM remains at the core of its potential
for personalized pharmaceuticals. Therefore, in an effort to
customize product features like the dose strength, FDM
multifunctionality must not be compromised. To harness this
advantage to its full extent, unlike currently demonstrated
FDM dose flexibility studies, which require high potencies
and/or large dosage forms for clinically relevant doses, our
results support preserved design flexibility via applicability to
a broad range of APIs of different potencies and solubilities.
The current work has demonstrated mean drug content
within ±5% of target values for all compositions and print
volumes but poor dispensing precision at all print volumes.
This pertinent result serves to highlight that whilst appropriate
material selection may favour the generation of stable, homo-
geneous, high drug content solid dispersions, dose flexibility
cannot be fully realised if the same materials do not exhibit
appropriate thermal, rheological and mechanical properties
for compatibility with FDM feeding mechanisms and nozzle
designs. Generating functional, fit-for-purpose dosage forms
has always relied upon material properties appropriate to
both processability and the delivery of desired functionalities,
however, for the purposes of promoting FDM flexibility, do-
ing so without severely restricting the range of materials that
can be used, remains crucial.
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